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Abstract
Background: Insulin resistance is one of the most important contributing factors to cardiovascular disease. This
study aimed to investigate the association between coronary artery stenosis (CAS) and triglyceride glucose index
(TyG index), a simple insulin resistance marker, in asymptomatic subjects with type 2 diabetes.
Methods: We recruited asymptomatic adults with type 2 diabetes but without previous history of coronary heart
disease (n = 888). Significant CAS was defined as maximum intraluminal stenosis ≥70 % by coronary CT
angiography. TyG index was calculated as log [fasting triglycerides (mg/dl) x fasting glucose (mg/dl)/2].
Results: Mean age was 63.8 ± 9.5 and 58.9 % of the subjects were men. We analyzed the participants according to
the tertile of TyG index. The TyG index was correlated with HOMA-IR (r = 0.397, P < 0.001), and subjects with higher
tertile of TyG index were younger but showed worse clinical and metabolic parameters. The prevalence of CAS was
higher in subjects with higher tertile of TyG compared with those with lower tertile of TyG (14 % vs. 7.8 %, P = 0.
022). On multiple regression analysis, the highest tertile of TyG index was an independent risk factor for CAS after
adjustment for other confounders (odds ratio, 3.19 [95 % CI, 1.371–7.424]). Subgroup analysis showed that TyG
index showed more significant association with CAS in patients with risk factors such as old age, longer duration of
diabetes, poor glycemic control, no statin use, and male gender.
Conclusion: Higher TyG index is associated with increased risk of CAS in asymptomatic subjects with type 2
diabetes, particularly when they have risk factors for cardiovascular disease.
Trial registration: This study was retrospectively registered in ClinicalTrials. gov with the registration number of
NCT02070926 in Feb 23, 2014.
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Background
Cardiovascular disease (CVD) is a major concern in sub-
jects with type 2 diabetes as it ultimately can lead to se-
vere morbidity and mortality. In type 2 diabetes,
macrovascular complications are the primary cause of
mortality, accounting for more than 50 % of all death
[1]. In addition to the high prevalence of CVD in type 2
diabetes, the recurrence rate of CVD is very high
(around 6 %/year) in subjects with type 2 diabetes and
prior CVD [2, 3]. In Korea, the prevalence of ischemic
heart disease is about 4 times greater in patients with
diabetes compared to those without diabetes [4]. Fur-
thermore, coronary intervention or bypass surgery was
performed at frequencies of up to 10-fold higher in pa-
tients with type 2 diabetes than those without diabetes
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[4]. Therefore, it is important to identify subjects at high
risk for CVD and to manage their condition early, par-
ticularly in those with type 2 diabetes.
One of the most important contributing factors to CVD
is insulin resistance, which refers to a decreased sensitivity
and responsiveness to the metabolic actions of insulin.
Insulin resistance predisposes to several disorders such as
hyperglycemia, hypertension, and dyslipidemia, all of
which are strongly associated with atherosclerosis. In
addition, insulin resistance contributes to vasoconstric-
tion, inflammation, and thrombosis, leading to accelerated
atherosclerosis. Previous studies have demonstrated an
independent association between insulin resistance and
clinical or subclinical CVD in both non-diabetic and
diabetic subjects [5–8]. In non-diabetic subjects, insulin
resistance is associated with the presence of coronary ar-
tery diseases and incident CVD [6, 7]. In diabetic subjects,
insulin resistance is associated with the thickening of the
carotid artery intima-media and incident CVD [5, 8].
Recently, a simple and inexpensive approach to evalu-
ate for insulin resistance has been developed [9]. This
particular test is based on measuring the product of fast-
ing triglycerides and glucose. Therefore, we aimed to in-
vestigate the association between CAS and triglyceride
glucose index (TyG index) in asymptomatic subjects
with type 2 diabetes. To the best of our knowledge, this
is the first study to investigate the association between
TyG index and CAD.
Methods
Study subjects and design
This study was an observational cohort study based on the
CRONOS-ADM Registry (Coronary CT angiography evalu-
ation for clinical outcomes in asymptomatic patients with
type 2 diabetes mellitus, registered with ClinicalTrials.gov
NCT02070926). We recruited asymptomatic subjects with
type 2 diabetes who underwent coronary CT angiography
between Jan 2006 and Dec 2010. In the present study, we
included subjects who were aged ≥18 years and had neither
a history of ischemic heart disease nor symptoms of angina.
We excluded those with type 1 diabetes, cardiac transplant-
ation, ventricular or supraventricular arrhythmias, and
ischemic heart disease such as coronary artery disease,
myocardial infarction, and coronary revascularization. Sub-
jects who had elevated triglyceride levels (>500 mg/dl) or
had taken antianginal medication or medications lowering
primarily triglycerides (fenofibrate, omega-3) were also
excluded. We measured blood glucose, fasting insulin, and
lipid profiles. HOMA-IR was calculated as insulin (mU/l) ×
(glucose [mg/dl] × 0.055)/22.5 [10]. The TyG index was
calculated by the logarithm of fasting triglyceride x fasting
glucose/2 [9]. Metabolic syndrome was assessed in those
whose waist circumference data were available (n = 280).
Metabolic syndrome was defined according to the revised
criteria of the National Cholesterol Education Program
Adult Treatment panel III (NCEP-ATP III) [11]. This
study protocol was conducted in full compliance with the
Declaration of Helsinki and was approved by the institu-
tional review board of Seoul St. Mary’s Hospital, The
Catholic University of Korea (No. KC15RISI0955). The
written informed consent from the participants was
waived by the institutional review board as only de-
identified data were accessed and analyzed.
Imaging protocol and analysis
Coronary CT angiography imaging was obtained using a
64-slice, dual source CT scanner (SOMATOM Definition,
Siemens, Forchheim, Germany). All patients were in
normal sinus rhythm and if the heart rate was faster than
70 beats per minute (bpm), intravenous beta blocker
(esmolol) was administered at a dose of 3 mg at 5-min
intervals up to three times. Images were obtained before
and after administration of 80–110 mL of iodinated con-
trast (Lomeron 350, iomeprol, Bracco, Milano, Italy). All
scans were performed using ECG-controlled tube current
modulation and the estimated radiation dose was less than
14 mSv. To obtain coronary artery images, all images were
reconstructed immediately after scan completion.
Coronary CT angiography images were analyzed by
two experienced radiologists. According to the guide-
lines of the Society of Cardiovascular Computed Tomog-
raphy [12], each segment of the coronary artery was
scored visually for the presence of a coronary plaque
using a 16-segment coronary artery model in an intent-
to-diagnose fashion. All analysis was performed only on
segments with a diameter ≥1.5 mm. Coronary plaques
were defined as structures ≥1 mm2 within or adjacent to
the coronary artery lumen, which were characterized
from the vessel lumen or surrounding pericardial tissues.
Significant CAS was diagnosed when there was severe
coronary artery stenosis, or when the maximum intra-
luminal stenosis in any of the segments of the major epi-
cardial coronary arteries was greater than 70 % [13].
Statistical analysis
Data are presented as mean ± standard deviations and
number (percentages). ANOVA and post hoc analysis
were performed to compare groups according to tertiles
of TyG index. For nonparametric variables, data are pre-
sented as median (interquartile range) and the Kruskal-
Wallis test was performed to compare three groups. Cat-
egorical variables were analyzed using the χ2 or Mantel-
Haenszel χ2 test. In order to adjust for age and sex, par-
tial Pearson’s correlation coefficient (R) was used to as-
sess the relationships between the two variables.
Multivariate logistic regression analysis was performed
in order to control for confounding factors. Subgroup
analysis was performed after categorizing the subjects
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according to age, sex, duration of diabetes, glycemic con-
trol, hypertension, and statin use. In subgroup analysis,
odds ratio was compared between the highest and lowest
tertile of TyG index. All statistical analyses were per-
formed using SPSS (version 20.0; IBM SPSS, NY, USA). A
P value <0.05 was considered statistical significant.
Results
Baseline characteristics according to the tertiles of TyG
index
Mean age was 63.9 ± 9.5 years and 58.9 % (n = 523) of
the study population (n = 888) were male. We analyzed
participants according to tertiles of TyG index. Subjects
in the higher tertile of TyG index were younger but had
greater BMI, WC, WHR, and blood pressure (Table 1).
Glycemic indices, such as plasma glucose and glycated
hemobgloin, and serum uric acid levels were higher
amongst subjects with higher tertile of TyG index. In
addition, subjects with higher tertile of TyG index
showed higher total and LDL-cholesterol levels but
lower HDL-cholesterol levels. There were no differences
in the duration of diabetes and renal function according
to the tertiles of TyG index. In subjects with higher ter-
tile of TyG index, more proportion used insulin and
metformin while α-glucosidase inhibitor and antiplatelet
agent use were less common. There was no difference in
statin use according to the tertiles of TyG index. At
baseline electrocardiography (ECG), 62 participants
showed left ventricular hypertrophy (n = 62, 7.0 %).
Other frequently observed changes in ECG were as
Table 1 Baseline characteristics of study population according to the tertiles of TyG index
Lowest tertile (n = 293) Mid tertile (n = 296) Highest tertile (n = 299) P value
Age (year) 65.4 ± 8.6 64.2 ± 9.3 62.0 ± 10.2*† <0.001
Male (%) 180 (61.4) 172 (58.1) 171 (57.2) 0.295
Duration of diabetes (year) 12.3 ± 9.3 12.2 ± 9.6 11.8 ± 9.3 0.779
BMI (kg/m2) 23.2 ± 3.1 24.6 ± 3.0* 24.9 ± 3.3* <0.001
WC (cm) 85.6 ± 8.5 89.8 ± 11.3* 89.8 ± 8.5* 0.005
WHR (cm) 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1* 0.010
SBP (mmHg) 123.7 ± 14.5 126.6 ± 13.3 127.0 ± 15.8* 0.016
DBP (mmHg) 73.2 ± 9.7 74.8 ± 9.5 77.0 ± 9.7*† <0.001
TyG index 8.2 ± 0.3 8.9 ± 0.2* 9.7 ± 0.4*† <0.001
HOMA-IR 2.1 (1.3–3.7) 3.9 (2.1–7.1) * 5.2 (3.2–10.1) *† <0.001
FPG (mg/dL) 117.1 ± 28.8 138.8 ± 31.6* 188.4 ± 71.1*† <0.001
PPG (mg/dL) 185.6 ± 65.8 205.6 ± 76.0* 245.6 ± 83.6*† <0.001
HbA1c (%) 7.4 ± 1.8 7.7 ± 1.9 8.8 ± 2.0*† <0.001
Total cholesterol (mg/dL) 155.5 ± 30.7 165.9 ± 32.8* 182.9 ± 42.5*† <0.001
Triglyceride (mg/dL) 68 (54–83) 115 (94–138)* 188 (145–253) *† <0.001
HDL cholesterol (mg/dL) 52.0 ± 13.4 46.5 ± 10.2* 44.2 ± 10.4* <0.001
LDL cholesterol (mg/dL) 89.9 ± 27.4 96.1 ± 29.7 97.4 ± 37.7* 0.009
Estimated GFR (mL/min/1.73 m2) 95.7 ± 24.6 93.8 ± 25.1 93.1 ± 24.2 0.125
Uric acid (mg/dL) 4.9 ± 1.3 5.0 ± 1.4 5.2 ± 1.6 0.046
Insulin, n (%) 59 (20.1) 66 (22.3) 83 (27.8) 0.028
Sulfonylurea, n (%) 117 (39.9) 127 (42.9) 109 (36.5) 0.383
Meglitinide, n (%) 39 (13.3) 33 (11.1) 35 (11.7) 0.551
Metformin, n (%) 161 (54.9) 193 (65.3) 202 (67.6) 0.002
Thiazolidinedione, n (%) 8 (2.7) 8 (2.7) 12 (4.0) 0.370
α-glucosidase inhibitor, n (%) 69 (23.5) 63 (21.3) 36 (12.0) <0.001
DPP-IV inhibitor, n (%) 19 (6.5) 25 (8.4) 22 (7.4) 0.689
Antiplatelet agent, n (%) 192 (66.2) 173 (58.6) 153 (51.7) <0.001
Statin, n (%) 151 (51.5) 176 (59.5) 138 (53.8) 0.580
Data are expressed as mean ± SD, median (interquartile range), or N (%). ACR, albumin to creatinine ratio; BMI body mass index, DBP diastolic blood pressure, DPP-
IV dipeptidyl peptidase IV, FPG fasting plasma glucose, GFR glomerular filtration rate, HDL high density lipoprotein, HOMA-IR homeostasis model assessment –
insulin resistance, LDL low density lipoprotein, PPG postprandial plasma glucose, SBP systolic blood pressure, WC waist circumference, WHR waist to hip ratio. * vs.
lowest tertile, † vs. mid tertile
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follows: first degree atrioventricular block (n = 37, 4.2 %),
right bundle branch block (n = 29, 3.3 %), atrial or ven-
tricular premature complex (n = 22, 2.5), atrial fibrilla-
tion (n = 3, 0.3 %), T wave inversion (n = 3, 0.3 %), ST
depression (n = 2, 0.2 %), and Q wave (n = 1, 0.1 %). The
frequencies of these ECG changes were not different
across the tertile of TyG index.
Association of TyG index with HOMA-IR and metabolic
syndrome
HOMA-IR values increased significantly according to
the tertiles of TyG index (Table 1). After adjusting for
age and sex, the TyG index was significantly correlated
with the HOMA-index (Fig. 1). The prevalence of meta-
bolic syndrome was significantly higher in subjects with
the highest tertile of TyG index compared to subjects of
the lowest tertile (84.1 % vs 39.4 %, P < 0.001). In
addition, features of metabolic syndrome, such as hyper-
tension, abdominal obesity, or low HDL-cholesterol were
more common amongst subjects with the higher tertiles
of TyG index (all P < 0.05).
Association of TyG index with CAS
Of the 888 subjects with asymptomatic type 2 diabetes,
109 (12.3 %) were found to have significant CAS on
MDCT. The prevalence of significant CAS was higher in
subjects with the higher tertile of TyG index (14 % for
the highest tertile of TyG index vs 7.8 % for the lowest
tertile of TyG index, P = 0.022). On multiple regression
analysis (Table 2), the higher tertile of TyG index was
significantly associated with CAS after adjusting for age
and sex (odds ratio, 2.36 [95 % GI, 1.370–4.078] for mid
tertile and 2.50 [1.432–4.348] for the highest tertile of
TyG index). After further adjustment for other con-
founding factors, such as glycemic control, blood pres-
sure, LDL-cholesterol and medications, the highest
tertile of TyG index was an independent risk factor for
CAS (odds ratio, 3.19 [95 % CI, 1.371–7.424]). As shown
in Fig. 2, subgroup analysis showed that subjects aged
≥60 years and with the highest tertile of TyG index had
an independent association with CAS (odds ratio, 2.78
[95 % CI, 1.085–7.124]). In addition, subjects with male
gender, longer duration of diabetes, and poor glycemic
control had higher odds ratios than those without these
risk factors. Subjects receiving insulin also showed
higher odds ratio compared to those without insulin
therapy. Meanwhile, subjects receiving antiplatelet agent
or statin had lower odds ratios compared to those with-
out these medications.
Discussion
In the present study, we observed that the TyG index
was correlated with HOMA-IR and that there were sig-
nificant differences in cardiometabolic parameters, in-
cluding the presence of metabolic syndrome, according
to the TyG index. In addition, we demonstrated that the
higher TyG index is associated with an increased risk of
CAS in asymptomatic subjects with type 2 diabetes. Fur-
thermore, subgroup analysis showed that the TyG index
is significantly associated with CAS in subjects with car-
diovascular risk factors such as older age, longer dur-
ation of diabetes, poor glycemic control, hypertension,
absence of statin or antiplatelet agents use, and male
gender. This suggests that the TyG index may be used as
a marker for insulin resistance and, importantly, to help
identify subjects at high risk of CVD.
Insulin resistance is a hallmark of type 2 diabetes and
even precedes the disease for several years [14]. Many
studies indicate that insulin resistance per se and associ-
ated disorders contribute to the development of CVD in
nondiabetic as well as diabetic subjects. It is well known
that insulin resistance is related to cardiometabolic risk
factors, such as hyperglycemia, dyslipidemia, and hyper-
tension. In addition, inflammatory and pro-coagulant
properties of insulin resistance may also lead to acceler-
ated atherosclerosis [14, 15]. For these reasons, insulin
resistance has been considered as not only a pathogenic
cause but also a predictor of CVD in type 2 diabetes.
Several prospective studies have shown that insulin re-
sistance predicts incident CVD in both the general and
diabetic subjects [5, 7, 16, 17]. In the general population,
insulin resistance, presented as HOMA-IR or metabolic
syndrome, was an independent predictor of CVD after
adjusting for other risk factors [7, 16, 17]. Similar results
were observed in subjects with type 2 diabetes and a
hazard ratio for CVD was significantly greater in
Fig. 1 Correlation between TyG index and HOMA-IR after adjustment
for age and sex
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subjects with diabetes compared with those without dia-
betes [5, 17].
In accordance with previous studies, we observed that
the TyG index, a marker for insulin resistance, was sig-
nificantly associated with CAS in asymptomatic subjects
with type 2 diabetes. The TyG index was first introduced
as a surrogate marker for insulin resistance by Guerreo-
Romero [9]. The TyG index has shown direct correlation
with insulin resistance, as assessed by hyperinsulinemic
euglycemic clamp or insulin-mediated glucose uptake
[18, 19]. In a Brazilian population, TyG index showed
better performance for assessing insulin resistance than
the HOMA-IR [20]. The TyG index showed similar cor-
relation with insulin resistance regardless of sex, obesity,
and diabetes [18]. This suggests that the TyG index
might be used in various populations as a biomarker of
insulin resistance. In addition, previous studies have re-
vealed that the TyG index has an independent associ-
ation with incident diabetes and carotid atherosclerosis
[20–22]. In the present study, we observed that the TyG
index was correlated with HOMA-IR and associated
with an increased prevalence of metabolic syndrome.
Taken together, the TyG index might be useful for the
identification of subjects with insulin resistance and as-
sociated disorders.
Several potential mechanisms have been suggested to
explain the correlation between TyG index and insulin
resistance. Increased triglyceride levels can lead to ele-
vated free fatty acids and, thus, increased flux of free
fatty acids from adipose to nonadipose tissue, which
Table 2 Multiple regression analysis for coronary artery stenosis
Model 1 Model 2 Model 3 Model 4
TyG index tertile OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value OR (95 % CI) P value
Lowest 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Mid 2.36 (1.370–4.078) 0.002 2.28 (1.313–3.967) 0.003 1.71 (0.729–3.991) 0.219 1.63 (0.674–3.924) 0.279
Highest 2.50 (1.432–4.348) 0.001 2.54 (1.418–4.544) 0.002 3.42 (1.519–7.709) 0.003 3.19 (1.371–7.424) 0.007
P for trend 0.002 0.002 0.002 0.006
Model 1: adjusted for age and sex
Model 2: model + adjusted for HbA1c and duration of diabetes
Model 3: model 2 + adjusted for systolic blood pressure, LDL cholesterol, estimated GFR, uric acid and smoking
Model 4: model 3 + adjusted for insulin, oral hypoglycemic agents, antiplatelet agents, antihypertensive medication, and statin
CI confidence interval, GFR glomerular filtration rate, OR odds ratio
Fig. 2 Subgroup analysis for coronary artery stenosis. Odds ratio of the highest tertile of TyG index was presented in comparison with the odds
ratio of the lowest tertile of TyG index
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may induce insulin resistance [23, 24]. Previous studies
have demonstrated that higher levels of triglycerides in
the liver and muscle may interfere with glucose metabol-
ism in each target organ [25–27]. These findings support
the importance of triglycerides in the pathogenesis of in-
sulin resistance and its possibility to be used as a surro-
gate marker for insulin resistance. Recently, there have
been growing evidence that some nutraceuticals in com-
mon diet lower plasma lipid levels and, thus, reduce the
overall cardiovascular risk [28]. In terms of TyG index, it
might be postulated that the effects of these nutraceuti-
cals on cardiovascular risk would be mediated by im-
proving insulin resistance.
Of note, the association between TyG index and CAS
was more significant in subjects with cardiovascular risk
factors such as older age, longer duration of diabetes,
poor glycemic control, lack of antiplatelet agent or statin
use, and male gender. This implies that greater insulin
resistance, as represented by the TyG index, makes sub-
jects more vulnerable to risk factors related to CVD.
Consistent with our results, high triglyceride levels has
been reported to be a predictor of incident or recurrent
CVD in subjects with type 2 diabetes [2, 29]. To prevent
CVD, aggressive management of modifiable risk factors
such as hyperglycemia, hypertension, or dyslipidemia in
subjects with cardiovascular risk factors and high TyG
index may be necessary. In contrast to other risk factors,
the association between TyG index and CAS was less
significant in subjects with hypertension. In our study,
more than 50 % of subjects with hypertension had taken
angiotensin receptor blocker or beta blocker. This may
contribute to the different results in subjects with
hypertension.
This study has several limitations. Firstly, as this study
has cross-sectional observation study design, we could
not evaluate for a direct causal relationship. Secondly,
we compared the TyG index with HOMA-IR rather than
the hyperinsulinemic euglycemic clamp, a gold standard
method for measuring insulin resistance. However, pre-
vious studies have shown similar associations between
the TyG index and insulin resistance, as measured by
the hyperinsulinemic euglycemic clamp, in a wide range
of subjects [18, 20]. Thirdly, the TyG index may not be
used in subjects with extremely high triglyceride levels
or in those taking medications that lower mainly triglyc-
erides. As more than 50 % of the participants had taken
statins, we only excluded subjects taking fenofibrate or
omega-3. Lastly, we could not adjust for alcohol, fruits,
juices, and other simple sugars consumption, which can
affect blood triglyceride levels. However, the measure-
ment of CAS by coronary CT angiography, as opposed
to surrogate markers such as intima-media thickness, is
a strength of this study. In addition, we analyzed data
with a relatively large sample size of asymptomatic
subjects with type 2 diabetes. One of the advantages of
the TyG index is that both the triglyceride and glucose
are usually measured in routine clinical practice and is,
therefore, readily available. The TyG index can also be
obtained by a simple equation and is less costly than the
insulin measurement.
Conclusions
In conclusion, the TyG index is associated with an in-
creased risk of CAS in asymptomatic subjects with
type 2 diabetes, particularly when they have other risk
factors. The TyG index may be used as a marker for
insulin resistance and help identify subjects at high
risk of CVD in asymptomatic subjects with type 2
diabetes. Further prospective studies are needed to in-
vestigate whether TyG index can predict cardiovascu-
lar events in these subjects.
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